SequelSEC

AGENUS INC AGEN

Biological Products, (No Diagnostic Substances) · CIK 0001098972 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$132.69M
Fiscal year ended 2026-06-30
Operating income
$36.20M
Fiscal year ended 2026-06-30
Free cash flow
-$98.50M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$135.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.53Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.0%3th
Current ratio0.41x11th
Gross margin99.1%88th
Operating margin-17.7%77th
SBC / revenue12.1%24th
R&D / revenue69.5%27th
FCF margin-67.6%67th
Revenue YoY growth10.4%53th

AGENUS INC (AGEN) reported revenue of $132.69M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from AGENUS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

AGENUS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$132.69M
Cost of revenue$642.00K
Gross profit$132.05M
Operating income$36.20M
Net incomeUnavailable
Research & development$57.69M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$38.48M
Selling & marketingUnavailable

Balance

AGENUS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$18.74M
Total assets$172.69M
Current assets$78.81M
Total liabilitiesUnavailable
Current liabilities$231.82M
Total equity incl. NCI-$205.85M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$14.72M
Goodwill$24.09M
Long-term debt$30.07M
Accounts payable$58.98M

Cash flow

AGENUS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$98.50M
Capital expenditures$0
Investing cash flow$70.08M
Financing cash flow$35.75M
Net change in cash$7.28M
Stock-based compensation$11.41M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$4.73M

Derived

AGENUS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$98.50M
Gross margin99.5%
Operating margin27.3%
FCF margin-74.2%
SBC / revenue8.6%
Current ratio0.34x
Revenue YoY growth30.5%
Net marginUnavailable
R&D / revenue43.5%
CapEx / revenue0.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AGEN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGTX AIM ALEC ALGS ALLO AMGN

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.